---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-061514"
form_type: "8-K"
ticker: "CALC"
cik: "0001534133"
company_name: "CalciMedica, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:40:13.260513+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CalciMedica Q3 net loss $4.6M; Auxora reduces hospital days 53% in AIPT trial

## Summary
- Net loss of $4.6M ($0.82/share) for Q3; cash $14.6M expected to fund through Q3 2024.
- Auxora Phase 1/2 CRSPA in AIPT: 53% reduction in hospital days, 40% ICU days, eliminated TPN vs 27 days historical control. Data at ASH Dec 2023.
- Phase 2b CARPO in acute pancreatitis with SIRS enrolling internationally; topline data H1 2024.
- Preparing IND for Auxora in acute kidney injury; Phase 2 could start H1 2024 subject to funding.
- Operating expenses $4.8M Q3; nine-month net loss $30.2M includes one-time merger charges.

## SEC filing metadata
- accession: 0000950170-23-061514
- form_type: 8-K
- ticker: CALC
- cik: 0001534133
- company_name: CalciMedica, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534133/000095017023061514/0000950170-23-061514-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534133/000095017023061514/calc-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-061514
- JSON: https://secwatch.observer/filing/0000950170-23-061514.json
- Plain text: https://secwatch.observer/filing/0000950170-23-061514.txt

## Key facts
- Earnings Releases
  CalciMedica, Inc. reported the third quarter ended September 30, 2023 results: net income Net loss was $4.6 million, or $0.82 per share (basic and diluted), EPS $0.82 per share (basic and diluted).
  - Period: the third quarter ended September 30, 2023
  - Net income: Net loss was $4.6 million, or $0.82 per share (basic and diluted)
  - EPS: $0.82 per share (basic and diluted)
  - Result: reported results
  source text: CalciMedica Inc. (“CalciMedica”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534133/000095017023061514/0000950170-23-061514-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.